Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), bought 43,500 shares at $0.80 ($35K) on 2025-01-27, disclosed to the SEC on 2025-01-29.
Open-market purchase of $35k PCSA by Chief Business - Strategy Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| PCSA | BUY | 2026-06-01 | $4K | — | Filing → |
| PCSA | BUY | 2026-05-19 | $4K | — | Filing → |
| PCSA | BUY | 2026-05-01 | $4K | — | Filing → |